1. Home
  2. CYBN vs SGHT Comparison

CYBN vs SGHT Comparison

Compare CYBN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYBN
  • SGHT
  • Stock Information
  • Founded
  • CYBN 2019
  • SGHT 2011
  • Country
  • CYBN Canada
  • SGHT United States
  • Employees
  • CYBN N/A
  • SGHT N/A
  • Industry
  • CYBN Pharmaceuticals and Biotechnology
  • SGHT Medical Specialities
  • Sector
  • CYBN Health Care
  • SGHT Health Care
  • Exchange
  • CYBN Nasdaq
  • SGHT Nasdaq
  • Market Cap
  • CYBN 178.7M
  • SGHT 179.7M
  • IPO Year
  • CYBN N/A
  • SGHT 2021
  • Fundamental
  • Price
  • CYBN $7.54
  • SGHT $3.27
  • Analyst Decision
  • CYBN Strong Buy
  • SGHT Buy
  • Analyst Count
  • CYBN 4
  • SGHT 8
  • Target Price
  • CYBN $85.00
  • SGHT $3.87
  • AVG Volume (30 Days)
  • CYBN 412.3K
  • SGHT 117.6K
  • Earning Date
  • CYBN 08-12-2025
  • SGHT 08-07-2025
  • Dividend Yield
  • CYBN N/A
  • SGHT N/A
  • EPS Growth
  • CYBN N/A
  • SGHT N/A
  • EPS
  • CYBN N/A
  • SGHT N/A
  • Revenue
  • CYBN N/A
  • SGHT $78,109,000.00
  • Revenue This Year
  • CYBN N/A
  • SGHT N/A
  • Revenue Next Year
  • CYBN N/A
  • SGHT $11.22
  • P/E Ratio
  • CYBN N/A
  • SGHT N/A
  • Revenue Growth
  • CYBN N/A
  • SGHT N/A
  • 52 Week Low
  • CYBN $4.81
  • SGHT $2.03
  • 52 Week High
  • CYBN $13.88
  • SGHT $7.78
  • Technical
  • Relative Strength Index (RSI)
  • CYBN 46.24
  • SGHT 39.19
  • Support Level
  • CYBN $7.26
  • SGHT $3.41
  • Resistance Level
  • CYBN $7.81
  • SGHT $3.63
  • Average True Range (ATR)
  • CYBN 0.45
  • SGHT 0.19
  • MACD
  • CYBN -0.04
  • SGHT -0.02
  • Stochastic Oscillator
  • CYBN 17.72
  • SGHT 23.19

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: